MCID: ADN015
MIFTS: 35

Adenoid Basal Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Adenoid Basal Cell Carcinoma

MalaCards integrated aliases for Adenoid Basal Cell Carcinoma:

Name: Adenoid Basal Cell Carcinoma 12 14
Skin Adenoid Basal Cell Carcinoma 12
Basal Cell Carcinoma - Adenoid 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4294

Summaries for Adenoid Basal Cell Carcinoma

MalaCards based summary : Adenoid Basal Cell Carcinoma, also known as skin adenoid basal cell carcinoma, is related to mannose-binding lectin protein deficiency and pseudounicornuate uterus. An important gene associated with Adenoid Basal Cell Carcinoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cell cycle Role of SCF complex in cell cycle regulation and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and liver, and related phenotypes are endocrine/exocrine gland and integument

Related Diseases for Adenoid Basal Cell Carcinoma

Diseases related to Adenoid Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
id Related Disease Score Top Affiliating Genes
1 mannose-binding lectin protein deficiency 10.7 KIT PGR
2 pseudounicornuate uterus 10.6 KIT PGR
3 thyroid angiosarcoma 10.6 KIT PGR
4 colon neuroendocrine neoplasm 10.6 KIT PGR
5 liver angiosarcoma 10.6 KIT PGR
6 placental insufficiency 10.6 B2M KIT
7 sebaceous adenoma 10.6 KIT PGR
8 spiradenoma 10.6 KIT PGR
9 extragonadal nonseminomatous germ cell tumor 10.6 KIT PGR
10 mesenchymoma 10.6 KIT PGR
11 diffuse meningeal melanocytosis 10.6 CDKN2A KIT
12 vulval paget's disease 10.6 CDKN2A KIT
13 epidermolytic acanthoma 10.6 B2M PGR
14 pancreatic agenesis 10.6 CDKN2A KIT
15 clear cell squamous cell skin carcinoma 10.6 KIT KRT7
16 pleuropneumonia 10.5 CDKN2A PGR
17 lynch syndrome 10.5 B2M KIT
18 leiomyoma cutis 10.5 CDKN2A PGR
19 nasal cavity squamous cell carcinoma 10.5 KIT PGR
20 exertional headache 10.5 CDKN2A KIT
21 olfactory neural tumor 10.5 B2M CDKN2A
22 facial hemiatrophy 10.5 CDKN2A KIT
23 bartholin's gland benign neoplasm 10.5 ESR1 PGR
24 central nervous system organ benign neoplasm 10.5 ESR1 PGR
25 gallbladder leiomyoma 10.5 ESR1 PGR
26 gallbladder papillomatosis 10.5 KIT KRT7
27 lung adenoma 10.5 ESR1 PGR
28 glaucoma, hereditary 10.5 ESR1 PGR
29 fallopian tube benign neoplasm 10.5 ESR1 PGR
30 paranasal sinus disease 10.5 ESR1 PGR
31 rectum kaposi's sarcoma 10.5 KIT PGR
32 dartoic leiomyoma 10.5 ESR1 PGR
33 urinary bladder inverted papilloma 10.5 ESR1 PGR
34 spinal cancer 10.5 ESR1 PGR
35 subglottis verrucous carcinoma 10.5 ESR1 PGR
36 deafness, autosomal dominant 8/12 10.5 ESR1 PGR
37 intestinal perforation 10.5 ESR1 PGR
38 her2-receptor positive breast cancer 10.5 ESR1 PGR
39 berk-tabatznik syndrome 10.5 KRT7 PGR
40 ovarian mesodermal adenosarcoma 10.5 ESR1 PGR
41 endophthalmitis 10.5 ESR1 PGR
42 gastroesophageal junction adenocarcinoma 10.4 ESR1 PGR
43 osteogenesis imperfecta 10.4 ESR1 PGR
44 bowman's membrane folds or rupture 10.4 KRT7 PGR
45 idiopathic juvenile osteoporosis 10.4 B2M CDKN2A
46 chest wall lymphoma 10.4 ESR1 PGR
47 cervical adenitis 10.4 CDKN2A KRT7
48 cutaneous mucoepidermoid carcinoma 10.4 ESR1 PGR
49 holoprosencephaly 6 10.4 ESR1 PGR
50 acute thyroiditis 10.4 ESR1 PGR

Graphical network of the top 20 diseases related to Adenoid Basal Cell Carcinoma:



Diseases related to Adenoid Basal Cell Carcinoma

Symptoms & Phenotypes for Adenoid Basal Cell Carcinoma

MGI Mouse Phenotypes related to Adenoid Basal Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.63 ESR1 KIT LALBA PGR B2M CDKN2A
2 integument MP:0010771 9.43 B2M CDKN2A ESR1 KIT LALBA PGR
3 neoplasm MP:0002006 9.1 B2M CDKN2A ESR1 KIT PGR SPN

Drugs & Therapeutics for Adenoid Basal Cell Carcinoma

Drugs for Adenoid Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
6
Doxepin Approved Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
9
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
10 Liver Extracts Phase 3,Phase 1,Phase 2
11 Adjuvants, Anesthesia Phase 3
12 Analgesics Phase 3
13 Analgesics, Opioid Phase 3
14 Anesthetics Phase 3
15 Anesthetics, General Phase 3
16 Anesthetics, Intravenous Phase 3
17 Central Nervous System Depressants Phase 3
18 Narcotics Phase 3
19 Peripheral Nervous System Agents Phase 3
20 Antifungal Agents Phase 2, Phase 3,Phase 1
21 Anti-Infective Agents Phase 2, Phase 3,Phase 1
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
23 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Hormones Phase 2, Phase 3,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
27 Steroid Synthesis Inhibitors Phase 2, Phase 3
28 Autonomic Agents Phase 3
29 Cholinergic Agents Phase 3
30 Neurotransmitter Agents Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Appetite Stimulants Phase 3
33 Central Nervous System Stimulants Phase 3
34 Contraceptive Agents Phase 3
35 Contraceptives, Oral Phase 3
36
Megestrol Phase 3 3562-63-8 19090 3080587
37 Antidepressive Agents Phase 3
38 Antidepressive Agents, Tricyclic Phase 3
39 Histamine Antagonists Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Psychotropic Drugs Phase 3
42 Antimitotic Agents Phase 3,Phase 2,Phase 1
43 Cola Nutraceutical Phase 3,Phase 1,Phase 2
44
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
45
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
46
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
47
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
48
Etoposide Approved Phase 2 33419-42-0 36462
49
Ifosfamide Approved Phase 2 3778-73-2 3690
50
Lenograstim Approved Phase 2,Phase 1 135968-09-1

Interventional clinical trials:

(show top 50) (show all 59)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
8 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
9 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
10 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
11 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
12 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
13 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
14 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
15 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
16 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
17 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
18 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
19 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
20 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
21 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
22 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
23 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
24 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
25 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
26 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
27 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1 systemic chemotherapy
28 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
29 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
30 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
31 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
32 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
33 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
34 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
35 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
36 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
37 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
38 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1 HPPH;photodynamic therapy
39 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Active, not recruiting NCT00851253 Phase 1
40 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
41 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
42 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
43 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 gefitinib
44 L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer Completed NCT01155609
45 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
46 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
47 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
48 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947
49 Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer Completed NCT00898300
50 PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy Completed NCT00809016

Search NIH Clinical Center for Adenoid Basal Cell Carcinoma

Genetic Tests for Adenoid Basal Cell Carcinoma

Anatomical Context for Adenoid Basal Cell Carcinoma

MalaCards organs/tissues related to Adenoid Basal Cell Carcinoma:

39
Skin, Lung, Liver, Brain, Breast, Kidney, Colon

Publications for Adenoid Basal Cell Carcinoma

Articles related to Adenoid Basal Cell Carcinoma:

id Title Authors Year
1
Adenoid basal cell carcinoma: a rare facet of basal cell carcinoma. ( 27095806 )
2016
2
CD117 and CD43 are useful adjuncts in the distinction of adenoid cystic carcinoma from adenoid basal cell carcinoma. ( 25551301 )
2015
3
Coexistence of Solid (Nodular) and Differentiated (Adenoid) Basal Cell Carcinoma at the Same Anatomical Site. ( 26538745 )
2015
4
Adenoid basal cell carcinoma and its mimics. ( 23723508 )
2013
5
Adenoid Basal cell carcinoma simulating ameloblastoma. ( 19549180 )
2009
6
A Case of Axillary Adenoid Basal Cell Carcinoma. ( 27303153 )
2008
7
Tenascin expression in adenoid basal cell carcinoma of the skin. ( 8615597 )
1996
8
Giant adenoid basal cell carcinoma. ( 8060083 )
1994
9
Primary adenoid cystic carcinoma of the skin. A clinical, histological, and immunocytochemical comparison with adenoid cystic carcinoma of salivary glands and adenoid basal cell carcinoma. ( 3010759 )
1986
10
Adenoid basal cell carcinoma of the vulva. ( 7185765 )
1982

Variations for Adenoid Basal Cell Carcinoma

Cosmic variations for Adenoid Basal Cell Carcinoma:

9 (show top 50) (show all 225)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44071 TP53 skin,NS,carcinoma,basal cell carcinoma c.955A>G p.K319E 7
2 COSM44097 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 7
3 COSM43635 TP53 skin,NS,carcinoma,basal cell carcinoma c.536A>T p.H179L 7
4 COSM43920 TP53 skin,NS,carcinoma,basal cell carcinoma c.680C>T p.S227F 7
5 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 7
6 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 7
7 COSM44436 TP53 skin,NS,carcinoma,basal cell carcinoma c.375+2T>C p.? 7
8 COSM10705 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 7
9 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 7
10 COSM45734 TP53 skin,NS,carcinoma,basal cell carcinoma c.622G>T p.D208Y 7
11 COSM44096 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>G p.P250A 7
12 COSM43616 TP53 skin,NS,carcinoma,basal cell carcinoma c.704A>G p.N235S 7
13 COSM43596 TP53 skin,NS,carcinoma,basal cell carcinoma c.841G>A p.D281N 7
14 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 7
15 COSM44310 TP53 skin,NS,carcinoma,basal cell carcinoma c.738G>A p.M246I 7
16 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 7
17 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 7
18 COSM11084 TP53 skin,NS,carcinoma,basal cell carcinoma c.517G>A p.V173M 7
19 COSM45138 TP53 skin,NS,carcinoma,basal cell carcinoma c.853G>C p.E285Q 7
20 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 7
21 COSM10887 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>G p.P278R 7
22 COSM44241 TP53 skin,NS,carcinoma,basal cell carcinoma c.592G>T p.E198* 7
23 COSM10660 TP53 skin,NS,carcinoma,basal cell carcinoma c.818G>A p.R273H 7
24 COSM44126 TP53 skin,NS,carcinoma,basal cell carcinoma c.507G>A p.M169I 7
25 COSM45751 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 7
26 COSM44130 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159A 7
27 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 7
28 COSM43842 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 7
29 COSM43695 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>T p.P250S 7
30 COSM11376 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 7
31 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 7
32 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 7
33 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 7
34 COSM45074 TP53 skin,NS,carcinoma,basal cell carcinoma c.829T>G p.C277G 7
35 COSM10863 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 7
36 COSM45739 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 7
37 COSM45322 TP53 skin,NS,carcinoma,basal cell carcinoma c.757A>G p.T253A 7
38 COSM44606 TP53 skin,NS,carcinoma,basal cell carcinoma c.665C>T p.P222L 7
39 COSM44295 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 7
40 COSM43665 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 7
41 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 7
42 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 7
43 COSM10771 TP53 skin,NS,carcinoma,basal cell carcinoma c.749C>T p.P250L 7
44 COSM44068 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 7
45 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 7
46 COSM45834 TP53 skin,NS,carcinoma,basal cell carcinoma c.409C>A p.L137M 7
47 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 7
48 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 7
49 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 7
50 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 7

Expression for Adenoid Basal Cell Carcinoma

Search GEO for disease gene expression data for Adenoid Basal Cell Carcinoma.

Pathways for Adenoid Basal Cell Carcinoma

Pathways related to Adenoid Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.38 CDKN2A ESR1 PGR
2 10.87 CEACAM5 KIT SPN

GO Terms for Adenoid Basal Cell Carcinoma

Cellular components related to Adenoid Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 B2M KIT SPN

Biological processes related to Adenoid Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 stem cell differentiation GO:0048863 9.26 ESR1 KIT
2 somatic stem cell division GO:0048103 8.96 CDKN2A KIT
3 response to cadmium ion GO:0046686 8.85 B2M
4 positive regulation of phospholipase C activity GO:0010863 8.62 ESR1 KIT

Molecular functions related to Adenoid Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 8.96 ESR1 PGR
2 steroid binding GO:0005496 8.62 ESR1 PGR

Sources for Adenoid Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....